|Day Low/High||5.01 / 5.01|
|52 Wk Low/High||3.30 / 7.16|
Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.
Sector M&A activity is likely to pick up next year benefiting the space.
The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.
The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.
Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.
Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise ahead.
Aratana Therapeutics and Kindred Biosciences are promising drug developers in the pet space.
Tech meltdown provides an opportunity for rotation into undervalued sectors.
This corrective action has me feeling optimistic about some new opportunities.
I wanted to start by congratulating El Capitan for his 12th anniversary for Mad Money tonight. Like the Energizer Bunny, he keeps going and going... HIgh yield gets junky -- despite protestations from Merrill's junk department! I have been warning ...
Companies developing drugs for cancer, eye problems and pets -- offer untapped value.
We answer recent reader questions about three of the biotech stocks we regularly cover.
Markets are slightly down in the early going. Gilead Science GILD is off about 9% on dismal revenue guidance for 2017 and price target downward revisions at various analyst firms. If 2017 projections do not light a fire under company to use mergers ...
"As to the markets, it trades like participants are sleeping off hangovers from partying hard during last night's Super Bowl thriller." -- "Is Another Lesson Soon to be Learned?" With such little price action it seemed like a snore fest (see above...
Market is showing a lack of interest today.
Market players are sorting out the winners and losers, and that produces good opportunities if we keep on digging.
This morning the most notable aspect of the action is the complete failure to bounce so far.
Animal health and oncology deal activity is heating up in 2017.
With poor breadth and money managers hiding in large-caps, I am being cautious, right now.
M&A activity should perk up substantially in the small and mid-cap space this year.
If the indices take out yesterday's lows I'll be very bearish very quickly.
This biopharma company's Relistor drug should send revenues sharply higher this year.
I've got my eye on steel and biotechnology names to put cash to work.
This biopharma company's Relistor drug should send revenues sharply higher next year.
Good picks make it easier to produce good results, but they are just a starting point.